Yang Yeon-ho's profile photo

Yang Yeon-ho

South Korea
Featured in: Favicon mk.co.kr Favicon pulsenews.co.kr

Articles

  • Jan 19, 2025 | pulse.mk.co.kr | Yang Yeon-ho |Han Yubin

    Bridge Biotherapeutics Inc. gave its first presentation at the Main Track of J.P. Morgan Healthcare Conference, the most informative healthcare symposium in the industry, as well as revealing promising clinical data for its idiopathic pulmonary fibrosis (IPF) drug candidate, BBT-877. The drugmaker began a Phase 2 clinical trial for the drug candidate for IPF, a rare lung disease that causes lung stiffening. The trial is in its final stages, with topline data expected in April 2025.

  • Jan 15, 2025 | pulse.mk.co.kr | Yang Yeon-ho |Minu Kim

    South Korea’s Celltrion has declared its ambitions to become a global leader in innovative drug development, with plans to accelerate its pipeline of next-generation antibody-drug conjugates (ADCs) and bispecific antibodies.

  • Dec 10, 2024 | pulse.mk.co.kr | Yang Yeon-ho |Minu Kim

    Samyang Foods Inc. has announced plans to expand into the microbiome business, focusing on gut microbiota transplantation technology as its first venture in the sector. The move aligns with the company’s strategy to position biotechnology as a core driver of growth. The initiative is expected to leverage synergies between its existing food and healthcare businesses.

  • Nov 12, 2024 | pulse.mk.co.kr | Yang Yeon-ho |Minu Kim

    The chairman of MAIN BIZ, an association of small and medium-sized enterprises that have achieved innovative results in management, outlined ambitious plans to foster communication-driven leadership and service-oriented leadership. The organization aims to activate inter-company networks and establish a premier platform for innovation that benefit member SMEs, Kim Myung-jin said in a recent interview with the Maeil Business Newspaper.

  • Nov 10, 2024 | pulse.mk.co.kr | Yang Yeon-ho |Lee Eun-joo

    Developing subcutaneous (SC) versions of antibody-drug conjugates (ADCs) will be a game-changing trigger in the highly competitive global landscape of ADC development, according to Alteogen Inc. Chief Executive Officer Park Soon-jae. “In the ADC field, only the first-in-class and best-in-class can ultimately survive,” Park said in a recent interview with Maeil Business Newspaper.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map